Cargando…
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide and available therapies, including immunotherapies, are ineffective for many patients. HCC is characterized by intratumoral hypoxia, and increased expression of hypoxia-inducible factor 1α (HIF-1α) in diagnostic biopsies i...
Autores principales: | Salman, Shaima, Meyers, David J., Wicks, Elizabeth E., Lee, Sophia N., Datan, Emmanuel, Thomas, Aline M., Anders, Nicole M., Hwang, Yousang, Lyu, Yajing, Yang, Yongkang, Jackson, Walter, Dordai, Dominic, Rudek, Michelle A., Semenza, Gregg L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057582/ https://www.ncbi.nlm.nih.gov/pubmed/35499076 http://dx.doi.org/10.1172/JCI156774 |
Ejemplares similares
-
Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice
por: Zhang, Jing, et al.
Publicado: (2023) -
NARF is a hypoxia-induced coactivator for OCT4-mediated breast cancer stem cell specification
por: Yang, Yongkang, et al.
Publicado: (2022) -
Histone citrullination by PADI4 is required for HIF-dependent transcriptional responses to hypoxia and tumor vascularization
por: Wang, Yufeng, et al.
Publicado: (2021) -
HIF-1 Interacts with TRIM28 and DNA-PK to release paused RNA polymerase II and activate target gene transcription in response to hypoxia
por: Yang, Yongkang, et al.
Publicado: (2022) -
Regulation of Osteogenesis-Angiogenesis Coupling by HIFs and VEGF
por: Schipani, Ernestina, et al.
Publicado: (2009)